Jean-François Dhainaut

Author

Université Paris Cité

Also Known As

Jean-Francois Dhainaut, Jean-François Dhainaut

Publications

6.1K

Citations

H-Index

Concepts

All Affiliations

Université Paris Cité Erasmus Hospital Rhode Island Hospital Massachusetts General Hospital University of Minnesota

About

Jean-François Dhainaut is an author at Université Paris Cité specializing in medicine, sepsis, and sepsis phenotyping.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	5.2K
2	International Health	2	2	5.1K
3	Critical Care Medicine	1	1	33
4	Emergency Medicine	1	1	33
5	Immunology	1	1	112

Jean-François Dhainaut

Publications

6.1K

Citations

H-Index

Page 1

	Year	Citations
Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 R. Phillip Dellinger, Mitchell M. Levy, Jean Carlet, Intensive Care Medicine Critical Care ManagementTrauma ResuscitationSevere SepsisAcute CarePatient Safety	2007	4.9K
Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569] Gary T. Kinasewitz, S. Betty Yan, Bruce R. Basson, Critical Care	2004	362
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment* Jean‐Louis Vincent, Gordon R. Bernard, Richard Beale, Critical Care Medicine	2005	320
Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 R. Phillip Dellinger, Mitchell M. Levy, Jean Carlet, Intensive Care Medicine Critical Care ManagementTrauma ResuscitationSevere SepsisAcute CarePatient Safety	2008	142
Recombinant Tissue Factor Pathway Inhibitor in Severe Community-acquired Pneumonia Richard G. Wunderink, Pierre-François Laterre, Bruno François, American Journal of Respiratory and Critical Care Medicine	2011	126
High levels of catalytic antibodies correlate with favorable outcome in sepsis Sébastien Lacroix‐Desmazes, Jagadeesh Bayry, Srini V. Kaveri, Proceedings of the National Academy of Sciences Severe SepsisHumoral ResponseImmunologyPathologyInflammation	2005	112
The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results* Jean-François Dhainaut, Pierre-François Laterre, Steven P. LaRosa, Critical Care Medicine	2003	92
Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock Jean-François Dhainaut, Massimo Antonelli, Patrick E. Wright, Intensive Care Medicine Trauma ResuscitationCritical Care MedicineAcute CarePatient SafetySepsis	2009	33

Page 1